Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results

Audit Opinion:

Limited Review Report issued by Deloitte Haskins & Sells with unmodified conclusion on both standalone and consolidated financial results.

Key Financial Highlights [₹ in million]:

Consolidated Results:

Revenue from Operations: ₹18,003 (Q1 FY27) vs ₹15,056 (Q1 FY26) - 20% YoY increase

Total Income: ₹18,615 (Q1 FY27) vs ₹15,631 (Q1 FY26)

EBITDA: ₹4,930 (Q1 FY27) vs ₹3,678 (Q1 FY26) - 34% YoY increase

EBITDA Margin: 27% (Q1 FY27) vs 24% (Q1 FY26)

Adjusted EBITDA: ₹5,102 (Q1 FY27) vs ₹3,737 (Q1 FY26) - 37% YoY increase

Adjusted EBITDA Margin: 28% (Q1 FY27) vs 25% (Q1 FY26)

Profit Before Tax: ₹4,350 (Q1 FY27) vs ₹3,127 (Q1 FY26) - 39% YoY increase

PBT Margin: 24% (Q1 FY27) vs 21% (Q1 FY26)

Net Profit: ₹3,170 (Q1 FY27) vs ₹2,155 (Q1 FY26) - 47% YoY increase

PAT Margin: 18% (Q1 FY27) vs 14% (Q1 FY26)

EPS (Basic): ₹19.23 (Q1 FY27) vs ₹13.08 (Q1 FY26)

EPS (Diluted): ₹19.22 (Q1 FY27) vs ₹13.08 (Q1 FY26)

Standalone Results:

Revenue from Operations: ₹12,866 (Q1 FY27) vs ₹10,388 (Q1 FY26)

Total Income: ₹13,455 (Q1 FY27) vs ₹10,936 (Q1 FY26)

Profit Before Tax: ₹3,643 (Q1 FY27) vs ₹2,692 (Q1 FY26)

Net Profit: ₹3,160 (Q1 FY27) vs ₹2,685 (Q1 FY26)

EPS (Basic): ₹22.10 (Q1 FY27) vs ₹16.34 (Q1 FY26)

EPS (Diluted): ₹22.11 (Q1 FY27) vs ₹16.34 (Q1 FY26)

Segment-wise Performance:

The Group operates in a single reportable business segment - "Pharmaceuticals" as per Ind AS 108 'Operating Segments'.

Business-wise Revenue Breakdown [₹ in million]:

CDMO Business: ₹8,915 (Q1 FY27) vs ₹7,411 (Q1 FY26) - 20% YoY growth

B2B Business: ₹9,088 (Q1 FY27) vs ₹7,645 (Q1 FY26) - 19% YoY growth

Total: ₹18,003 (Q1 FY27) vs ₹15,056 (Q1 FY26) - 20% YoY growth

Geographical Revenue Breakdown [₹ in million]:

USA: ₹9,810 (Q1 FY27) vs ₹7,443 (Q1 FY26) - 32% YoY growth

Europe: ₹3,954 (Q1 FY27) vs ₹3,302 (Q1 FY26) - 20% YoY growth

Canada, Australia, New Zealand: ₹534 (Q1 FY27) vs ₹739 (Q1 FY26) - 28% YoY decline

India: ₹666 (Q1 FY27) vs ₹594 (Q1 FY26) - 12% YoY growth

Rest of World: ₹3,039 (Q1 FY27) vs ₹2,978 (Q1 FY26) - 2% YoY growth

Corporate Actions:

Not Specified

Other Significant Information:

R&D Investments: ₹772 million in Q1 FY27 (4% of consolidated revenue)

New Launches: 4 molecules launched in USA including Multi-Vitamin and Leucovorin calcium

ANDA Filings: 3 new ANDAs filed in Q1 FY27, cumulative total 389 ANDA filings in US (342 approved, 47 pending)

ANDA Approvals: 7 ANDAs approved in Q1 FY27

Complex Pipeline: 6 products launched, 3 more in line for approval

Co-development Partnerships: 15 products in co-development (7 505(b)(2) and 8 ANDAs)

RTU Bags: 21 products filed, 18 approved, 11 under development addressing $644 million US market opportunity

CDMO Partnership: With global pharmaceutical company with annualized revenue potential of USD 90-100 million once commercialized (expected commencement from calendar year 2029)

Strategic Collaboration: With Neuland Laboratories for manufacturing sterile APIs for microparticle depot products

In-licensing Agreement: With China-based development company for niche liposomal product for US and European markets

Entities included in consolidation:

1. Gland Pharma Limited (Holding Company)

2. Gland Pharma International Pte. Ltd., Singapore (Wholly-owned subsidiary)

3. Gland Pharma USA Inc., USA (Wholly-owned subsidiary)

4. Gland Pharma (USA) "1" Inc., France (Wholly-owned subsidiary)

5. Gland Pharma (USA) "1" Inc., France (Wholly-owned subsidiary)

6. CIS SAS, France (Wholly-owned subsidiary)

7. CIS SAS, France (Wholly-owned subsidiary)

8. CIS Laboratoire Thissen SA, Belgium (Wholly-owned subsidiary)

9. Phix SAS, Belgium (Wholly-owned subsidiary)

10. Gland Pharma Europe SAS, France (Wholly-owned subsidiary)